Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

IMMUNOGEN, INC. (IMGN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 05/23 10:00:00 pm
10.375 USD   +0.63%
05/17IMMUNOGEN,INC. : IMGN) Files An 8-K Other Events
AQ
05/16IMMUNOGEN : Announces Positive Findings from the FORWARD II Study of..
BU
05/04IMMUNOGEN : 1Q Earnings Snapshot
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

FDA Approves Kadcyla, Breast-Cancer Drug from Roche, ImmunoGen

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 05:26pm CEST
   By Jennifer Corbett Dooren 
 

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline PLC's (GSK, GSK.LN) Tykerb. The drugs were administered every three weeks until the disease progressed or patients experienced unmanageable side effects.

The study was designed to measure progression-free survival, which is a measurement of the time from the start of treatment until the disease gets worse or the patient dies, and overall survival, which is a measurement of time from the start of treatment until death.

The median progression-free survival for patients receiving T-DM1 was 9.6 months, compared with 6.4 months in the group receiving Xeloda and Tykerb, a difference considered statistically significant. The median overall survival was 30.9 months in the Kadcyla group and 25.1 months for Xeloda and Tykerb group.

Write to Jennifer Corbett Dooren at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : ImmunoGen, Inc.
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -0.11% 1507.6 Delayed Quote.13.18%
IMMUNOGEN, INC. 0.68% 10.38 Delayed Quote.60.22%
ROCHE HOLDING LTD. -2.08% 219.25 Delayed Quote.-8.90%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOGEN, INC.
05/17IMMUNOGEN,INC. (NASDAQ : IMGN) Files An 8-K Other Events
AQ
05/17IMMUNOGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16IMMUNOGEN : Announces Positive Findings from the FORWARD II Study of Mirvetuxima..
BU
05/09IMMUNOGEN : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
05/04IMMUNOGEN : 1Q Earnings Snapshot
AQ
05/04IMMUNOGEN INC : Results of Operations and Financial Condition, Financial Stateme..
AQ
05/04IMMUNOGEN : Reports Recent Progress and First Quarter 2018 Operating Results
BU
05/04IMMUNOGEN, INC. : to Host Earnings Call
AC
05/02IMMUNOGEN : Announces Webcast of Presentation at Deutsche Bank’s 43rd Annu..
BU
04/27IMMUNOGEN : Here’s Why The Immunogen News Is Important For The Company
AQ
More news
News from SeekingAlpha
05/18ImmunoGen (IMGN) Forward II Program Update - Slideshow 
05/17ImmunoGen's mirventuximab soravtansine shows positive effect in early-stage o.. 
05/16Biotechs perk up ahead of ASCO abstract drop 
05/09IMMUNOGEN : An Extremely Promising ADC Therapeutic Innovator 
05/04ImmunoGen's (IMGN) CEO Mark Enyedy on Q1 2018 Results - Earnings Call Transcr.. 
Financials ($)
Sales 2018 64,1 M
EBIT 2018 -140 M
Net income 2018 -151 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 21,4x
EV / Sales 2019 15,2x
Capitalization 1 372 M
Chart IMMUNOGEN, INC.
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | 4-Traders
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 13,0 $
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
Mark J. Enyedy President, Chief Executive Officer & Director
Stephen C. McCluski Chairman
David B. Johnston Chief Financial Officer & Executive Vice President
Richard J. Gregory Chief Scientific Officer & Executive VP
Anna Berkenblit Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOGEN, INC.60.22%1 372
CELLTRION, INC.--.--%31 419
IQVIA HOLDINGS INC4.83%21 259
LONZA GROUP1.41%20 379
INCYTE CORPORATION-29.48%14 109
NEKTAR THERAPEUTICS42.83%14 033